Key result
Polycystic ovary syndrome in adolescent girls was associated with a higher prevalence of metabolic syndrome compared to healthy controls (10.4% vs. 0% based on the Ferranti scale).
Why the study?
Is polycystic ovary syndrome associated with an increased prevalence of metabolic syndrome in adolescent girls?
Case-Control (n=115)
Is polycystic ovary syndrome associated with an increased prevalence of metabolic syndrome in adolescent girls?
Absolute Event Rate: 10.4% vs 0%
Adolescent girls with PCOS have a significantly higher prevalence of metabolic syndrome compared to healthy peers, highlighting the need for early cardiovascular risk screening.
Supports early cardiovascular risk screening in adolescents with PCOS; leaves open whether targeted metabolic interventions at this age.
Background Metabolic syndrome (MS) in adolescents is a risk factor for type 2 diabetes and cardiovascular diseases. Objective The present study aimed to determine the prevalence of MS in 14-18-year-old girls. Methods This analytical case-control study was conducted on 3200 high school students with polycystic ovarian syndrome (PCOS). PCOS was confirmed by an endocrinologist after detection of clinical hyperandrogenism (acne, hirsutism and alopecia) and oligomenorrhea, rejection of hypothyroidism and hyperprolactinemia and performance of abdominal sonography. In the second stage, the prevalence of MS was compared between 70 girls with PCOS and 45 healthy girls using the ATPIII, Cooki and Ferranti scales. The study data were collected using a demographic questionnaire, body mass index (BMI) graph, the WC graph and standard blood pressure graph in adolescents. Then, the data were analyzed using the t-test and the χ2-test. Results Based on the Ferranti scale, the prevalence of MS was 10.4% and 0% in the case and control groups, respectively. The highest prevalence was related to hyperandrogenism and polycystic ovaries phenotype (11.6% vs. 0%, p = 0.05). Based on the Cooki and ATPIII scales, the prevalence of this disorder was 4.1% in the case group and 0.67% in the control group, with the highest rate being related to hyperandrogenism, oligomenorrhea and polycystic ovaries phenotype (7.5% vs. 0%, p = 0.28). Conclusion In comparison to the control group, the prevalence of MS in the patients with PCOS was 10-fold higher according to the Ferranti scale and nearly 3.5-fold higher based on the Cooki and ATPIII scales. Thus, long-term follow-up is suggested in these patients.
No takes yet. Share an insight, caveat, or question.
Dabbaghmanesh et al. (2017) conducted a case-control in Polycystic ovary syndrome (n=115). Polycystic ovary syndrome vs. Healthy controls was evaluated on Prevalence of metabolic syndrome based on the Ferranti scale. Polycystic ovary syndrome in adolescent girls was associated with a higher prevalence of metabolic syndrome compared to healthy controls (10.4% vs. 0% based on the Ferranti scale).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: